BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 20679884)

  • 21. The incidence of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion in Saudi adult patients with renal cancer: a retrospective tissue microarray analysis.
    Al-Maghrabi J; Mufti S; Gomaa W
    Pol J Pathol; 2018; 69(4):376-383. PubMed ID: 30786687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.
    Fukuda H; Kato I; Furuya M; Tanaka R; Takagi T; Kondo T; Nagashima Y
    Virchows Arch; 2019 Mar; 474(3):389-393. PubMed ID: 30552521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MiT family translocation renal cell carcinoma.
    Argani P
    Semin Diagn Pathol; 2015 Mar; 32(2):103-13. PubMed ID: 25758327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis.
    Klatte T; Streubel B; Wrba F; Remzi M; Krammer B; de Martino M; Waldert M; Marberger M; Susani M; Haitel A
    Am J Clin Pathol; 2012 May; 137(5):761-8. PubMed ID: 22523215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
    Malouf GG; Camparo P; Oudard S; Schleiermacher G; Theodore C; Rustine A; Dutcher J; Billemont B; Rixe O; Bompas E; Guillot A; Boccon-Gibod L; Couturier J; MoliniƩ V; Escudier B
    Ann Oncol; 2010 Sep; 21(9):1834-1838. PubMed ID: 20154303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular-genetic analysis is essential for accurate classification of renal carcinoma resembling Xp11.2 translocation carcinoma.
    Hayes M; Peckova K; Martinek P; Hora M; Kalusova K; Straka L; Daum O; Kokoskova B; Rotterova P; PivovarĨikova K; Branzovsky J; Dubova M; Vesela P; Michal M; Hes O
    Virchows Arch; 2015 Mar; 466(3):313-22. PubMed ID: 25544614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An Xp11.2 translocation renal cell carcinoma with SMARCB1 (INI1) inactivation in adult end-stage renal disease: a case report.
    Yu L; Li J; Xu S; Navia Miranda M; Wang G; Duan Y
    Diagn Pathol; 2016 Oct; 11(1):98. PubMed ID: 27733182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case of bilateral renal cell carcinoma associated with long-term dialysis showing false-positive immunoreactivity for TFE3 as Xp11 translocation renal cell carcinoma.
    Kurisaki-Arakawa A; Saito T; Takahashi M; Mitani K; Fukumura Y; Nagashima Y; Argani P; Yao T
    Int J Clin Exp Pathol; 2013; 6(11):2585-90. PubMed ID: 24228124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA expression profiling of Xp11 renal cell carcinoma.
    Marchionni L; Hayashi M; Guida E; Ooki A; Munari E; Jabboure FJ; Dinalankara W; Raza A; Netto GJ; Hoque MO; Argani P
    Hum Pathol; 2017 Sep; 67():18-29. PubMed ID: 28411178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic Contrast-Enhanced CT Characterization of Xp11.2 Translocation/TFE3 Gene Fusions versus Papillary Renal Cell Carcinomas.
    He J; Zhou K; Zhu B; Zhang G; Li X; Guo H; Gan W; Zhou Z; Liu T
    Biomed Res Int; 2015; 2015():298679. PubMed ID: 26636097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting chemoresistance in Xp11.2 translocation renal cell carcinoma using a novel polyamide-chlorambucil conjugate.
    Funasaki S; Mehanna S; Ma W; Nishizawa H; Kamikubo Y; Sugiyama H; Ikeda S; Motoshima T; Hasumi H; Linehan WM; Schmidt LS; Ricketts C; Suda T; Oike Y; Kamba T; Baba M
    Cancer Sci; 2022 Jul; 113(7):2352-2367. PubMed ID: 35396773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.
    Ellis CL; Eble JN; Subhawong AP; Martignoni G; Zhong M; Ladanyi M; Epstein JI; Netto GJ; Argani P
    Mod Pathol; 2014 Jun; 27(6):875-86. PubMed ID: 24309327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of immunohistochemistry, FISH and RT-PCR shows high incidence of Xp11 translocation RCC: comparison of three different diagnostic methods.
    Lee HJ; Shin DH; Noh GY; Kim YK; Kim A; Shin N; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Rha SH; Park SW
    Oncotarget; 2017 May; 8(19):30756-30765. PubMed ID: 28415646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pediatric renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions and clinicopathologic associations.
    Altinok G; Kattar MM; Mohamed A; Poulik J; Grignon D; Rabah R
    Pediatr Dev Pathol; 2005; 8(2):168-80. PubMed ID: 15747097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity.
    Rao Q; Shen Q; Xia QY; Wang ZY; Liu B; Shi SS; Shi QL; Yin HL; Wu B; Ye SB; Li L; Chen JY; Pan MH; Li Q; Li R; Wang X; Zhang RS; Yu B; Ma HH; Lu ZF; Zhou XJ
    Am J Surg Pathol; 2015 Sep; 39(9):1181-96. PubMed ID: 26274027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic pitfall on the histological spectrum of adult-onset renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.
    Kuroda N; Katto K; Tanaka Y; Yamaguchi T; Inoue K; Ohara M; Mizuno K; Hes O; Michal M; Lee GH
    Med Mol Morphol; 2010 Jun; 43(2):86-90. PubMed ID: 20683695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Xp11.2 translocation renal cell carcinoma with PSF-TFE3 rearrangement.
    Zhong M; Weisman P; Zhu B; Brassesco M; Yang Y; Linehan WM; Merino MJ; Zhang D; Rohan S; Cai D; Yang X
    Diagn Mol Pathol; 2013 Jun; 22(2):107-11. PubMed ID: 23628822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions with focus on pathobiological aspect.
    Kuroda N; Mikami S; Pan CC; Cohen RJ; Hes O; Michal M; Nagashima Y; Tanaka Y; Inoue K; Shuin T; Lee GH
    Histol Histopathol; 2012 Feb; 27(2):133-40. PubMed ID: 22207547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinomas.
    Mosquera JM; Dal Cin P; Mertz KD; Perner S; Davis IJ; Fisher DE; Rubin MA; Hirsch MS
    Diagn Mol Pathol; 2011 Sep; 20(3):129-37. PubMed ID: 21817901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adult-onset renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusion with smooth muscle stroma and abnormal vessels.
    Kuroda N; Tamura M; Tanaka Y; Hes O; Michal M; Inoue K; Ohara M; Mizuno K; Lee GH
    Pathol Int; 2009 Jul; 59(7):486-91. PubMed ID: 19563413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.